Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 627 News
1 - 10of about 627 News
June 23, 2021
Not intended for U.S. and UK Media
Vericiguat approved in Japan to treat patients with chronic heart failure
READ MORE
June 21, 2021
Not intended for U.S. and UK Media
Bayer submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EU
READ MORE
June 08, 2021
Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson’s disease
READ MORE
June 03, 2021
Not intended for U.S. and UK Media
Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
READ MORE
May 27, 2021
Bayer announces five-point plan to effectively address potential future Roundup™ claims
READ MORE
May 25, 2021
Not intended for U.S. and UK Media
Precision oncology treatment Larotrectinib submitted for marketing authorization in China
READ MORE
May 21, 2021
Not intended for U.S. and UK Media
Positive CHMP opinion for Bayer’s new symptomatic chronic heart failure treatment vericiguat
READ MORE
May 19, 2021
Not intended for U.S. and UK Media - ASCO Annual Meeting 2021:
Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical benefit of greater than four years in patients with TRK fusion cancer regardless of tumor type and age
READ MORE
May 17, 2021
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
READ MORE
May 17, 2021
Not intended for U.S. and UK Media - Late-Breaking Data from exploratory analysis of Phase III FIDELIO-DKD study presented at the American College of Cardiology’s (ACC) 70th Annual Scientific Session (ACC.21)
Finerenone has potential to reduce the risk of new onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes
READ MORE
1 - 10of about 627 News
1 - 10of about 627 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more